Glaucoma Clinical Trial
Official title:
Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures
NCT number | NCT02154217 |
Other study ID # | LR-BLT |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | May 21, 2014 |
Last updated | May 29, 2014 |
Verified date | May 2014 |
Source | University of Milan |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: Ethics Committee |
Study type | Interventional |
This is a data revision with a focus on 24 hour perfusion pressures of data from a previous
randomized, double masked, multicenter clinical trial.
The aim was to compare the effect of bimatoprost and the fixed combination of latanoprost
and timolol (LTFC) on 24-hour mean intraocular pressure (IOP) after patients are switched
from a nonfixed combination of latanoprost and timolol.
The main findings of the original trial had been published on Ophthalmology [2007;114:
2244-2251].
Status | Completed |
Enrollment | 200 |
Est. completion date | |
Est. primary completion date | December 2004 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patients diagnosed as having POAG (primary open-angle glaucoma) or ocular hypertension and 18 years or older who fulfilled the eligibility requirements detailed below and signed an informed consent at the screening visit were included. Two different groups of patients were potentially eligible: 1. Those patients who were controlled (IOP< 21 mmHg) on the nonfixed combination of latanoprost and timolol (twice daily or once daily morning administration) for at least 3 months prior to the baseline visit. 2. Patients on monotherapy either with latanoprost or timolol who were eligible for dual therapy being not satisfactorily controlled (IOP < 21 mmHg, or, as judged by the physician, target IOP was not reached). Pseudoexfoliation glaucomas and patients with diabetes were not excluded. Exclusion Criteria: All patients in whom beta-blockers were contraindicated were excluded. Ocular Condition. 1. Closed/barely open anterior chamber angles (ACAs) or history of acute angle closure. The ACA was viewed by means of the Goldmann 1-mirror lens. Shaffer grading was used, and grades II, III, and IV were included. Grades 0 and I were excluded. 2. Ocular surgery or argon laser trabeculoplasty within the last 3 months. 3. Ocular inflammation/infection occurring within 3 months before the pretrial visit. 4. Neovascular glaucomas. 5. Hypersensitivity to benzalkonium chloride or to any other component of the trial drug solutions. 6. Other abnormal ocular condition or symptom preventing the patient from entering the trial, according to the investigator's judgement. 7. Patients on either bimatoprost or the LTFC. 8. Patients who had undergone refractive surgery. General 9. Inability to adhere to treatment/visit plan. 10. Participation in any other clinical trial (i.e., requiring in- formed consent) within 1 month before the prestudy visit. 11. Pregnancy, nursing, or, if applicable, nonuse of adequate contraception. 12. Any drug known to affect IOP. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Universitaets-augenklinik | Dresden | |
Germany | Universitaets-augenklinik | Magdeburg | |
Greece | Department of Ophthalmology, University of Thessaly, University Hos- pital of Larissa | Larissa | |
Greece | II Department of Ophthalmology, Aristotle University of Thessaloniki | Thessaloniki | |
Italy | Clinica Oculistica, Dipartimento di Oftalmologia-Otorinolaringoiatria, Universita` di Bari | Bari | |
Italy | A.O. San Paolo | Milan | Lombardy |
Italy | Clinica Oculistica, Universita` degli studi di Roma, Tor Vergata | Rome | |
Switzerland | Universita¨ts-Augenklinik, Inselspital, University of Bern | Bern | |
United Kingdom | Moorfields Eye Hospital, | London |
Lead Sponsor | Collaborator |
---|---|
University of Milan |
Germany, Greece, Italy, Switzerland, United Kingdom,
Rossetti L, Karabatsas CH, Topouzis F, Vetrugno M, Centofanti M, Boehm A, Viswanathan A, Vorwerk C, Goldblum D. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Ophthalmology. 2 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in mean diastolic and systolic perfusion pressures | The Primary outcome was the difference in mean diastolic and systolic perfusion pressures after bimatoprost and the LTFC | Baseline - Week 2 - Week 6 - Week 12 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A |